Plain-English translation of NCT05208710 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is one of the first times this treatment has been tested in people.
This early-stage trial is testing a new vaccine called PANHPVAX that aims to prevent cancers caused by human papillomavirus (HPV). Unlike existing HPV vaccines that only protect against a few virus types, this medication is designed to work against many different cancer-causing HPV types at once. Researchers will give healthy volunteers different doses of the vaccine through three injections to see if it's safe and if the body's immune system responds well to it.
Current HPV vaccines protect against only a limited number of virus types, leaving people vulnerable to other cancer-causing HPV strains. This medication targets a part of the virus that is shared across many different HPV types, potentially offering broader protection against HPV-related cancers like cervical cancer, other genital cancers, throat cancer, and skin cancers.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will receive three injections of the vaccine (given into your arm muscle) spaced several weeks apart. The doses will start low and gradually increase across different groups of participants to find the safest and most effective dose. You'll have multiple visits to the clinic for injections and blood tests to check your health and measure your immune response. The entire trial will take several months, and you'll need to avoid other HPV vaccines and certain medications during this time.
AI-generated summary from trial data · Oct 12, 2026 · Not medical advice
Germany